Sameed Ahmed M Khatana1,2,3, Thomas C Hanff1,2, Ashwin S Nathan1,2,3, Elias J Dayoub1,2,3, E Wilson Grandin4,5, J Eduardo Rame6, Alexander C Fanaroff1,2,3, Jay Giri1,2,3, Peter W Groeneveld2,3,7,8. 1. Division of Cardiovascular Medicine (S.A.M.K., T.C.H., A.S.N., E.J.D., A.C.F., J.G.), Perelman School of Medicine, University of Pennsylvania, PA. 2. Penn Cardiovascular Outcomes, Quality, & Evaluative Research Center (S.A.M.K., T.C.H., A.S.N., E.J.D., A.C.F., J.G., P.W.G.), Perelman School of Medicine, University of Pennsylvania, PA. 3. The Leonard Davis Institute of Health Economics (S.A.M.K., A.S.N., E.J.D., A.C.F., J.G., P.W.G.), Perelman School of Medicine, University of Pennsylvania, PA. 4. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology (E.W.G.), Beth Israel Deaconess Medical Center, Boston, MA. 5. Division of Cardiology (E.W.G.), Beth Israel Deaconess Medical Center, Boston, MA. 6. Jefferson Heart Institute, Thomas Jefferson University Hospital, Pennsylvania, PA (J.E.R.). 7. Division of General Internal Medicine, Perelman School of Medicine (P.W.G.), Perelman School of Medicine, University of Pennsylvania, PA. 8. Center for Health Equity Research and Promotion, Michael J. Crescenz Veterans Affairs Medical Center, Pennsylvania, PA (P.W.G.).
Abstract
BACKGROUND: Due to the high cost of left ventricular assist device (LVAD) therapy, payer type may be an important factor in determining eligibility. How payer type influences outcomes after LVAD implantation is unclear. We, therefore, aimed to study the association of health insurance payer type with outcomes after durable LVAD implantation. METHODS: Using STS-INTERMACS (Society of Thoracic Surgeons-Interagency Registry for Mechanically Assisted Circulatory Support), we studied nonelderly adults receiving a durable LVAD from 2016 to 2018 and compared all-cause mortality and postindex hospitalization adverse event episode rate by payer type. Multivariable Fine-Gray and generalized linear models were used to compare the outcomes. RESULTS: Of the 3251 patients included, 26.0% had Medicaid, 24.9% had Medicare alone, and 49.1% had commercial insurance. Compared with commercially insured patients, mortality did not differ for patients with Medicaid (subdistribution hazard ratio, 1.00 [95% CI, 0.75-1.34], P=0.99) or Medicare (subdistribution hazard ratio, 1.09 [95% CI, 0.84-1.41], P=0.52). Medicaid was associated with a significantly lower adjusted incidence rate (incidence rate ratio, 0.88 [95% CI, 0.78-0.99], P=0.041), and Medicare was associated with a significantly higher adjusted incidence rate (incidence rate ratio, 1.16 [95% CI, 1.03-1.30], P=0.011) of adverse event episodes compared with commercially insured patients. CONCLUSIONS: All-cause mortality after durable LVAD implantation did not differ significantly by payer type. Payer type was associated with the rate of adverse events, with Medicaid associated with a significantly lower rate, and Medicare with a significantly higher rate of adverse event episodes compared with commercially insured patients.
BACKGROUND: Due to the high cost of left ventricular assist device (LVAD) therapy, payer type may be an important factor in determining eligibility. How payer type influences outcomes after LVAD implantation is unclear. We, therefore, aimed to study the association of health insurance payer type with outcomes after durable LVAD implantation. METHODS: Using STS-INTERMACS (Society of Thoracic Surgeons-Interagency Registry for Mechanically Assisted Circulatory Support), we studied nonelderly adults receiving a durable LVAD from 2016 to 2018 and compared all-cause mortality and postindex hospitalization adverse event episode rate by payer type. Multivariable Fine-Gray and generalized linear models were used to compare the outcomes. RESULTS: Of the 3251 patients included, 26.0% had Medicaid, 24.9% had Medicare alone, and 49.1% had commercial insurance. Compared with commercially insured patients, mortality did not differ for patients with Medicaid (subdistribution hazard ratio, 1.00 [95% CI, 0.75-1.34], P=0.99) or Medicare (subdistribution hazard ratio, 1.09 [95% CI, 0.84-1.41], P=0.52). Medicaid was associated with a significantly lower adjusted incidence rate (incidence rate ratio, 0.88 [95% CI, 0.78-0.99], P=0.041), and Medicare was associated with a significantly higher adjusted incidence rate (incidence rate ratio, 1.16 [95% CI, 1.03-1.30], P=0.011) of adverse event episodes compared with commercially insured patients. CONCLUSIONS: All-cause mortality after durable LVAD implantation did not differ significantly by payer type. Payer type was associated with the rate of adverse events, with Medicaid associated with a significantly lower rate, and Medicare with a significantly higher rate of adverse event episodes compared with commercially insured patients.
Entities:
Keywords:
Medicaid; Medicare; health insurance; heart failure; heart-assist devices; quality of health care
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: Circulation Date: 2017-04-28 Impact factor: 29.690
Authors: Robert L Kormos; Jennifer Cowger; Francis D Pagani; Jeffrey J Teuteberg; Daniel J Goldstein; Jeffrey P Jacobs; Robert S Higgins; Lynne W Stevenson; Josef Stehlik; Pavan Atluri; Kathleen L Grady; James K Kirklin Journal: J Heart Lung Transplant Date: 2019-02 Impact factor: 10.247
Authors: Antonio Polanco; Andrew M Breglio; Shinobu Itagaki; Andrew B Goldstone; Joanna Chikwe Journal: Heart Surg Forum Date: 2012-10 Impact factor: 0.676
Authors: Hossein Bahrami; Richard Kronmal; David A Bluemke; Jean Olson; Steven Shea; Kiang Liu; Gregory L Burke; João A C Lima Journal: Arch Intern Med Date: 2008-10-27